Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVABEL: Bevacizumab with Gemcitabine and Platinum for Metastatic Collecting Duct Carcinoma
NCT02363751Phase 2Completed
- Sponsor
- Unicancer
- Start
- Dec 2014
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in collecting duct carcinoma of the kidney (CDC), renal medullary carcinoma (RMC), sponsored by Unicancer. Started Dec 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
collecting duct carcinoma of the kidney (CDC)renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT02363751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363751.